Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: Results from the European Prospective Investigation into Cancer and Nutrition

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 6, 2007, Pages 1121-1127

  Allen, Naomi E ^a   Key, Timothy J ^a   Appleby, Paul N ^a   Travis, Ruth C ^a   Roddam, Andrew W ^a   Rinaldi, Sabina ^b   Egevad, Lars ^b   Rohrmann, Sabine ^c   Linseisen, Jakob ^c   Pischon, Tobias ^d   Boeing, Heiner ^d   Johnsen, Nina Føns ^e   Tjønneland, Anne ^e   Grønbæk, Henning ^f   Overvad, Kim ^g   Kiemeney, Lambartus ^h   Bueno de Mesquita, H Bas ⁱ   Bingham, Sheila ^j   Kay, Tee Khaw ^k   Tumino, Rosario ^l   Berrino, Franco ^m   Mattiello, Amalia ⁿ   Sacerdote, Carlotta ^o   Palli, Domenico ^p   Quirós, José Ramón ^q   Ardanaz, Eva ^r   Navarro, Carmen ^s   Larrañaga, Nerea ^t   Gonzalez, Carlos ^u   Sanchez, Maria José ^v   Trichopoulou, Antonia ^w   Travezea, Cryssoula ^w   Trichopoulos, Dimitrios ^x   Jenab, Mazda ^b   Ferrari, Pietro ^b   Riboli, Elio ^y   Kaaks, Rudolf ^c   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^e INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

^g AALBORG UNIVERSITY HOSPITAL   (Denmark)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^j UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^k UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^l CIVILE M P AREZZO HOSPITAL   (Italy)

^m NATIONAL CANCER INSTITUTE   (Italy)

ⁿ UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^o Center for Cancer Prevention CPO Piemonte   (Italy)

^p CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^q Public Health and Health Planning Directorate   (Spain)

^r INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^s DEPARTMENT OF EPIDEMIOLOGY   (Spain)

^t Basque Government   (Spain)

^u CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^v ANDALUSIAN SCHOOL OF PUBLIC HEALTH   (Spain)

^w UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^x HELLENIC HEALTH FOUNDATION   (Greece)

^y IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 34250887614     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-1062     Document Type: Article

References (32)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No. 5 version 2.0. Lyon: IARC Press; 2004.
2. Wolk A. Diet, lifestyle and risk of prostate cancer. Acta Oncol 2005;44: 277-81.
3. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34.
4. Pollak M. Insulin-like growth factor physiology and cancer risk. Eur J Cancer 2000;36:1224-8.
5. Cohen P, Peehl DM, Lamson G, Rosenfeld RG. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 1991;73:401-7.
6. Iwamura M, Sluss PM, Casamento JB, Cockett AT. Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate 1993;22:243-52.
7. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-h1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 1997;272:12181-8.
8. Harrela M, Koistinen H, Kaprio J, et al. Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest 1996;98:2612-5.
9. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363:1346-53.
10. Chen C, Lewis SK, Voigt L, Fitzpatrick A, Plymate SR, Weiss NS. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. Cancer 2005;103:76-84.
11. Janssen JA, Wildhagen MF, Ito K, et al. Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval. J Clin Endocrinol Metab 2004;89:4391-6.
12. Meyer F, Galan P, Douville P, et al. A prospective study of the insulin-like growth factor axis in relation with prostate cancer in the SU.VI.MAX trial. Cancer Epidemiol Biomarkers Prev 2005;14:2269-72.
13. Platz EA, Pollak MN, Leitzmann MF, Stampfer MJ, Willett WC, Giovannucci E. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes Control 2005;16:255-62.
14. Woodson K, Tangrea JA, Pollak M, et al. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res 2003;63:3991-4.
15. Severi G, Morris HA, Macinnis RJ, et al. Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15:1137-41.
16. Morris JK, George LM, Wu T, Wald NJ. Insulin-like growth factors and cancer: no role in screening. Evidence from the BUPA study and metaanalysis of prospective epidemiological studies. Br J Cancer 2006;95:112-7.
17. Oliver SE, Gunnell D, Donovan J, et al. Screen-detected prostate cancer and the insulin-like growth factor axis: results of a population-based case-control study. Int J Cancer 2004;108:887-92.
18. Chan JM, Stampfer MJ, Ma J, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002;94:1099-106.
19. Lacey JVJ, Hsing AW, Fillmore CM, Hoffman S, Helzlsouer KJ, Comstock GW. Null association between insulin-like growth factors, insulin-like growth factor-binding proteins, and prostate cancer in a prospective study. Cancer Epidemiol Biomarkers Prev 2001;10:1101-2.
20. Schaefer C, riedman GD, Quesenberry CP. IGF-I and prostate cancer. Science 1998;282:199.
21. Stattin P, Bylund A, Rinaldi S, et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins and prostate cancer risk: a prospective study. J Natl Cancer Inst 2000;92:1910-7.
22. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6.
23. Harman SM, Metter EJ, Blackman MR, Landis PK, Carter HB. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab 2000;85:4258-65.
24. Riboli E, Hunt KJ, Slimani N, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 2002;5:1113-24.
25. Hunter DJ, Riboli E, Haiman CA, et al. A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer 2005;5:977-85.
26. Kaaks R, Rinaldi S, Lukanova A, Akhmedkhanov A, Zeleniuch-Jacquotte A, Toniolo P. Correspondence re: A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 2001;10:1103-4.
27. Rinaldi S, Kaaks R, Zeleniuch-Jacquotte A, et al. Insulin-like growth factor-I, IGF binding protein-3, and breast cancer in young women: a comparison of risk estimates using different peptide assays. Cancer Epidemiol Biomarkers Prev 2005;14:48-52.
28. Montironi R, Mazzuccheli R, Scarpelli M, Lopez-Beltran A, Fellegara G, Algaba F. Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: contemporary approach, current clinical significance and sources of pathology discrepancies. BJU Int 2005;95:1146-52.
29. Bostwick DG. Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies. Am J Surg Pathol 1994;18:796-803.
30. Decensi A, Johansson H, Miceli R, et al. Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer. Cancer Epidemiol Biomarkers Prev 2001;10:1047-53.
31. Kaaks R, Toniolo P, Akhmedkhanov A, et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 2000;92:1592-600.
32. Lukanova A, Zeleniuch-Jacquotte A, Lundin E, et al. Prediagnostic levels of C-peptide, IGF-I, IGFBP-1, -2 and -3 and risk of endometrial cancer. Int J Cancer 2004;108:262-8.